Business Context and Reporting Period
This Form 8-K is a current report filed by Athira Pharma, Inc. (not Leonabio, Inc.) on December 11, 2020. The registrant is a Delaware corporation with its principal executive offices in Seattle, WA. The report addresses corporate governance changes effective immediately upon the filing date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
- Board Appointment: The Board of Directors appointed Kelly A. Romano as a director, effective December 11, 2020.
- Committee Assignment: Ms. Romano was appointed to the Audit Committee.
- Term: Ms. Romano serves as a Class III director with a term expiring at the 2023 annual meeting of stockholders.
- Compensation: Ms. Romano received an initial stock option grant effective December 11, 2020, under the Company's standard compensation plan for non-employee directors. She also entered into a standard indemnification agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No risks, contingencies, or unusual items are disclosed in this specific report. The document confirms there are no undisclosed transactions or arrangements between Ms. Romano and the Company.
Investor Verification Checklist
- Verify the exact terms of the initial stock option grant provided to Ms. Romano in the referenced Form S-1 (File No. 333-248428).
- Review the press release attached as Exhibit 99.1 for additional context on the appointment.
- Confirm the composition of the Audit Committee following this appointment.
- Note that the company name in the metadata request (Leonabio) differs from the registrant in the filing (Athira Pharma).